- Home
- CMAX vs PRPO Comparison
CMAX vs PRPO Comparison
Compare CMAX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMAX
- PRPO
- Stock Information
- Founded
- CMAX 2011
- PRPO N/A
- Country
- CMAX United States
- PRPO United States
- Employees
- CMAX N/A
- PRPO N/A
- Industry
- CMAX Computer Software: Prepackaged Software
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- CMAX Technology
- PRPO Industrials
- Exchange
- CMAX Nasdaq
- PRPO Nasdaq
- Market Cap
- CMAX 7.6M
- PRPO 9.6M
- IPO Year
- CMAX N/A
- PRPO N/A
- Fundamental
- Price
- CMAX $1.85
- PRPO $6.70
- Analyst Decision
- CMAX Hold
- PRPO
- Analyst Count
- CMAX 2
- PRPO 0
- Target Price
- CMAX $33.20
- PRPO N/A
- AVG Volume (30 Days)
- CMAX 58.0K
- PRPO 7.7K
- Earning Date
- CMAX 11-07-2024
- PRPO 11-11-2024
- Dividend Yield
- CMAX N/A
- PRPO N/A
- EPS Growth
- CMAX N/A
- PRPO N/A
- EPS
- CMAX N/A
- PRPO N/A
- Revenue
- CMAX $784,551,000.00
- PRPO $16,719,999.00
- Revenue This Year
- CMAX $13.01
- PRPO $75.18
- Revenue Next Year
- CMAX $32.42
- PRPO N/A
- P/E Ratio
- CMAX N/A
- PRPO N/A
- Revenue Growth
- CMAX 9.06
- PRPO 52.61
- 52 Week Low
- CMAX $1.55
- PRPO $4.31
- 52 Week High
- CMAX $74.70
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- CMAX 46.01
- PRPO 52.82
- Support Level
- CMAX $1.60
- PRPO $6.42
- Resistance Level
- CMAX $2.39
- PRPO $6.99
- Average True Range (ATR)
- CMAX 0.19
- PRPO 0.33
- MACD
- CMAX 0.07
- PRPO -0.04
- Stochastic Oscillator
- CMAX 32.50
- PRPO 69.91
About CMAX CareMax Inc.
CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.